We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY - Free Report) will announce quarterly loss of $0.75 per share in its forthcoming report, representing an increase of 46.4% year over year. Revenues are projected to reach $421.1 million, increasing 31.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Alnylam metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Product revenues, net' at $344.00 million. The estimate indicates a year-over-year change of +24.5%.
Analysts' assessment points toward 'Royalty revenue' reaching $18.66 million. The estimate suggests a change of +187.1% year over year.
According to the collective judgment of analysts, 'Net revenues from research collaborators' should come in at $58.26 million. The estimate suggests a change of +59.8% year over year.
Analysts forecast 'Net Product Revenue- Oxlumo' to reach $32.68 million. The estimate indicates a change of +35.3% from the prior-year quarter.
Analysts expect 'Net Product Revenues- Givlaari' to come in at $60.32 million. The estimate indicates a year-over-year change of +25.9%.
The consensus estimate for 'Net Product Revenues- Onpattro' stands at $63.24 million. The estimate points to a change of -38.3% from the year-ago quarter.
Over the past month, shares of Alnylam have returned -3.9% versus the Zacks S&P 500 composite's -2.5% change. Currently, ALNY carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY - Free Report) will announce quarterly loss of $0.75 per share in its forthcoming report, representing an increase of 46.4% year over year. Revenues are projected to reach $421.1 million, increasing 31.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Alnylam metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Product revenues, net' at $344.00 million. The estimate indicates a year-over-year change of +24.5%.
Analysts' assessment points toward 'Royalty revenue' reaching $18.66 million. The estimate suggests a change of +187.1% year over year.
According to the collective judgment of analysts, 'Net revenues from research collaborators' should come in at $58.26 million. The estimate suggests a change of +59.8% year over year.
Analysts forecast 'Net Product Revenue- Oxlumo' to reach $32.68 million. The estimate indicates a change of +35.3% from the prior-year quarter.
Analysts expect 'Net Product Revenues- Givlaari' to come in at $60.32 million. The estimate indicates a year-over-year change of +25.9%.
The consensus estimate for 'Net Product Revenues- Onpattro' stands at $63.24 million. The estimate points to a change of -38.3% from the year-ago quarter.
View all Key Company Metrics for Alnylam here>>>
Over the past month, shares of Alnylam have returned -3.9% versus the Zacks S&P 500 composite's -2.5% change. Currently, ALNY carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>